Neuvasq Biotechnologies

TLDR

Neuvasq Biotechnologies develops first-in-class Gpr124- and Reck-targeting Wnt surrogate antibodies to restore blood-retina and blood-brain barriers.

Overview

Neuvasq Biotechnologies is pioneering the development of first-in-class Gpr124- and Reck-targeting Wnt surrogate antibodies, designed to restore the integrity of the blood-retina and blood-brain barriers. This approach targets vascular retinopathies such as diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), as well as severe neurological disorders.